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Exclusion criteria: Sedation commenced more than six hours before inclusion; patients with septic, hemorrhagic or carcinogenic shock; head-trauma patients; Glasgow Coma Scale less than nine; pregnancy; breast feeding; acute bleeding; preexisting neurological disease with conscious disorder; personal family history of malignant hyperthermia; chronic renal failure; cirrhosis with Child' s class C; severe cardiac impairment or cardiac rhythm disorders; lack of consent.
Study group: (n=20, 19 analysed -one excluded as sedation was stopped before 24 hours). Patients were randomised to receive sedation with sevoflurane.
Control groups: (n=20, 14 analysed -one excluded as sedation was stopped before 24 hours, two patients were excluded as the intervention was discontinued, and three patients were excluded due to loss of follow-up data). Patients were randomised to receive sedation with propofol (n=20, 14 analysed -three were excluded as the intervention was discontinued, and three were excluded due to loss of follow-up data). Patients were randomised to receive sedation with midazolam.
EBM questions: 1. Do the methods allow adequate testing of the hypothesis?
Probably. Although the study was not blinded, it was a well-designed randomised controlled trial, with all patients well matched for baseline characteristics. It did however have some limitations:
Inhaled sevoflurane for long-term sedation
Inhaled sevoflurane is a safe and effective alternative to intravenous propofol or midazolam for long-term sedation on the intensive care unit Level of evidence: 1B (CEBM, RCT of good quality)
Appraised by: L Helliwell, R Sachdeva, A Whitehouse
The evidence:
CAT reviews
• The subjective assessment of the nurses taking the necessary measurements could have been biased. • The exclusion criteria resulted in the studied population being relatively young. The majority were trauma patients.
Extrapolating the results to a larger population is difficult. 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes. 3. Are the conclusions valid in light of the results? Yes. The authors conclude that long-term sedation with sevoflurane is a safe and effective alternative to propofol or midazolam. They do not draw any conclusions that are not supported by statistically significant results, and they also suggest the results should be applied with caution to a larger population due to the limitations mentioned above. 4. Did results get omitted? Yes. Of the 60 patients randomised, two were excluded as their sedation lasted less than 24 hours, five patients were excluded as the intervention was discontinued, and six patients were excluded as there was a loss of follow-up data due to heavy nursing and physician workloads. Many patients did not fulfil the strict inclusion criteria for the study. 5. Did they suggest further areas of research? Yes. The authors were aware of the limitations of the study and the need for further research with a larger group of patients. They also suggest that their finding of lower morphine requirements in the sevoflurane group could be through inhibition of NMDA receptors; however, this would require further investigation. 6. Did they make any recommendations based on the results and were they appropriate? No. The authors suggested that using sevoflurane via an ACD for long-term sedation of patients on the ICU was a safe alternative to a propofol-or midazolam-based regimen. The trial was not designed to determine the difference in ICU outcome or mortality.
Although it was associated with significantly better outcomes, they do not make any specific recommendations for its use over midazolam or propofol. 7. Is the study relevant to my clinical practice? Yes. In our tertiary trauma centre, we receive many patients on the ICU with similar demographics to those in this trial. The benefits such as reduced wake-up times and shorter delays to extubation would make inhaled sevoflurane an alternative for long-term sedation, worth considering. 8. What level of evidence does this study represent? 1B (CEBM,
RCT of good quality) This is a randomised controlled trial but impossible to blind and therefore carries a risk of bias. 9. What grade of recommendation can I make on this study alone?
B (CEBM 
